New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

Core Viewpoint - Ipsen presented 14 abstracts at the TOXINS 2026 conference, showcasing the effectiveness of Dysport® (abobotulinumtoxinA) in treating various neurological conditions, particularly post-stroke spasticity, cervical dystonia, and blepharospasm, while also highlighting new indications under evaluation [1][5]. Group 1: Study Findings - An interim analysis from the EPITOME study revealed that 45.7% of stroke survivors with paresis developed post-stroke spasticity (PSS) within one year, an increase from the previously documented 39.5% [2][3][5]. - The study emphasizes the importance of early identification of PSS through a Post-stroke Spasticity Monitoring Questionnaire, which aids clinicians in detecting early signs of spasticity [2][3]. Group 2: Treatment Gaps - Less than 1% of stroke survivors receive BoNT-A treatment for spasticity in routine practice, indicating a significant care gap in the management of post-stroke spasticity [3][5]. - The existing evidence suggests that remote monitoring can facilitate timely intervention, potentially improving rehabilitation outcomes and quality of life for patients [3]. Group 3: Ipsen's Commitment - Ipsen's Executive Vice President, Chief Medical Officer, emphasized the company's mission to address care gaps for individuals with neurological conditions through comprehensive data presentation and studies like EPITOME [4]. - The company aims to provide standardized follow-up care to ensure stroke survivors receive the necessary treatment [4]. Group 4: Dysport Overview - Dysport® (abobotulinumtoxinA) is an injectable botulinum neurotoxin type A product that has been authorized in approximately 90 countries, with over 30 years of clinical experience and more than 18 million treatment years of patient experience [7].